Inclusion Criteria:

          1. Subject is ≥18 to ≤75 years of age at the time of signing the study informed consent.

          2. Subject has histologically confirmed diagnosis of any one of the following cancers:
             (A) urothelial cancer (transitional cell cancer of the bladder, ureter or renal
             pelvis), (B) melanoma, or (C) squamous cell carcinoma of the head and neck.

          3. Subject is HLA-A*02:01 and/or HLA-A*02:06 positive.

          4. Subject has measurable disease according to RECIST v1.1 criteria prior to
             lymphodepletion

          5. Subject meets disease-specific requirements per protocol

          6. Subject has anticipated life expectancy > 6 months prior to leukapheresis and >3
             months prior to lymphodepletion.

          7. Subject's tumor shows positive MAGE-A10 expression

          8. Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

          9. Subject has a left ventricular ejection fraction ≥50%.

         10. Subject is fit for leukapheresis and has adequate venous access for the cell
             collection.

         11. Female subject of childbearing potential (FCBP) must have a negative urine or serum
             pregnancy test or male subject must be surgically sterile or agree to use a double
             barrier contraception method or abstain from heterosexual activity with a female of
             childbearing potential starting at the first dose of chemotherapy and for 4 months
             thereafter.

         12. Subject must have adequate organ function per protocol

        Exclusion Criteria:

          1. Subject is HLA-A*02:05 in either allele, HLA-B*15:01 and/or HLA-B*46:01 positive.
             Subject has any A*02 null allele (designated with an "N", e.g. A*02:32N) as the sole
             HLA-A*02 allele.

          2. Subject has received or plans to receive excluded therapy/treatment prior to
             leukapheresis or lymphodepleting chemotherapy per protocol

          3. Subject that has toxicity from previous anti-cancer therapy must have recovered to ≤
             Grade 1 prior to enrollment

          4. Subject has history of allergic reactions attributed to compounds of similar chemical
             or biologic composition to fludarabine, cyclophosphamide or other agents used in the
             study.

          5. Subject had major surgery within 4 weeks prior to lymphodepletion; subjects should
             have been fully recovered from any surgical related toxicities.

          6. Subject has an electrocardiogram (ECG) showing clinically significant abnormality at
             Screening or showing an average QTc interval ≥450 msec in males and ≥470 msec in
             females (≥480 msec for subjects with bundle branch block [BBB]) over 3 consecutive
             ECGs. Either Fridericia's or Bazett's formula may be used to correct the QT interval.

          7. Subject has symptomatic CNS metastases.

          8. Subject has a history of chronic or recurrent severe autoimmune or immune mediated
             disease

          9. Subject has any other active malignancy besides the tumor under study within 3 years
             prior to Screening.

         10. Subject has uncontrolled intercurrent illness

         11. Subject has active infection with HIV, HBV, HCV or HTLV

         12. Subject is pregnant or breastfeeding.